-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Prior studies have shown that the secretion of acidic proteins-
rich in cysteine-like protein
1 (SPARCL1)increases synaptic stability through axon regenerationThe purpose of this study was to determine the correlation between serumSPARCL1concentrations and the severity of severe traumatic brain injury(sTBI)and hospitalization mortalitythe study included 102sTBIpatients and 102randomly selected healthy controls inMultifactoranalysis were used to detect serumSPARCL1 concentrations and to analyze the scores and hospitalization mortality rates of the Glasgow Coma Scale (GCS) studies showed that with the control group (median, 0.22 ng / ml; The tetradigit range, 0.19-0.41ng/ml ), patients significantly increased concentration of SPARCL1 (median, 3.29ng/ml; Quartile range, 1.88-4.37; P 0.001 ) there is an independent correlation between the concentration of the sPARCL1 and the GCS score (
t s.7.011 , P 0.001 ) found high area to predict in-hospital mortality (
AUC , 0.822; 95
% confidence interval, 0.734-0.891 ) under the recipient operating curve (
AUC ) of serum SPAR CL1 concentrations In the multi-logical regression analysis, the serum SPARCL1 concentration 3.29ng/ml independently related to in-hospital mortality (advantage ratio is 10.052, 95 % confidence interval 1.918-52.686 , P is 0.006 ) , the new findings of this study are that there is an increase in serum SPARCL1 in patients with sTBI , and a correlation between high serum SPARCL1 concentrations and sTBI mortality or trauma severity